Pharmaceutical Biotech (2269.HK): New projects continue to grow and maintain the 24-year guideline
Pharmaceutical Biotech (02269.HK): Steady overall growth in non-COVID-19 revenue continues to improve global production capacity layout
WUXI BIOLOGICS(2269.HK):1H24 MARGINS DECLINED;US REVENUE PROPORTION EXPANDED TO 58%
Pharmaceutical Biotech (2269.HK): Newly signed projects continue to increase, and the three major RDM sectors will accelerate improvement in the second half of the year
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$19.30 From HK$23.25, Keeps at Buy
Pharmaceutical Biotech (2269.HK): 1H24's performance is in line with expectations, but short-term uncertainty remains, maintaining a neutral rating
Pharmaceutical Biotech (02269.HK): XDC achieved rapid growth and remained unchanged in the 2024 full-year guideline
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$23.25 From HK$53.65, Keeps at Buy
Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target Is HK$14
Big Bank Rating | Jefferies: The upward potential of Pharmaceutical Biotech is greater than the downward potential rating “buy”
Big Bank Ratings | Jefferies: From the perspective of market accounts, Yao Ming Biotech is currently at an inflection point rating “buying”
Big Bank Ratings | Jefferies: From the perspective of market accounts, Yao Ming Biotech is currently at an inflection point rating “buying”
Research and Development | China Merchants Securities: Drastic reduction in the target price of Pharmaceutical Biotech to HK$13, downgrading the rating to “neutral”
Pharmaceutical Biotech (02269.HK): Opening a New Chapter in Global Operations, Multiple Engines Drive Growth
Pharmaceutical Biotech (2269.HK): The non-COVID-19 business continues to grow rapidly while the industry gradually recovers
Pharmaceutical Biotech (2269.HK) 2023 Report Review: Steady growth in revenue and profit is optimistic that the company's multiple technology platforms will drive the long-term growth of integrated CRDMO leaders
Pharmaceutical Biotech (02269.HK): The non-COVID-19 business maintained a high growth rate and the trend of new orders in 24 years was good
Pharmaceutical Biotech (02269.HK): Steady growth in the non-COVID-19 business, global production capacity layout continues to advance
WUXI BIOLOGICS(02269.HK):REBOUND OF THE NUMBER OF NEW PROJECTS
Pharmaceutical Biotech (2269.HK): Performance is in line with expectations, overseas production capacity is gradually being implemented